Seguridad y supervivencia de las terapias biológicas: primer informe del registro paraguayo-uruguayo de acontecimientos adversos con terapias biológicas Biobadaguay

Sanmarti, 2015, 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis, Reumatol Clin., 11, 279 Feldmann, 2001, Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?, Annu Rev Immunol., 19, 163, 10.1146/annurev.immunol.19.1.163 Curtis, 2011, Use of biologics in rheumatoid arthritis: current and emerging paradigms of care, Clin Ther., 33, 679, 10.1016/j.clinthera.2011.05.044 Kremers, 2009, Methods to analyze real-world databases and registries, Bull NYU Hosp Jt Dis., 67, 193 Curtis, 2010, A comparison of patient characteristics and outcomes in selected European and nd U.S. rheumatoid arthritis registries, Semin Arthritis Rheum., 40, 2, 10.1016/j.semarthrit.2010.03.003 Ventura-Rios, 2012, Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0, Reumatol Clin., 8, 189 Titton, 2011, Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results, Rev Bras Reumatol., 51, 152, 10.1590/S0482-50042011000200005 De la Vega, 2016, Características de los tratamientos biológicos en enfermedades reumáticas en Argentina: quinto informe del registro Biobadasar, Rev Arg Reumatol., 27, 14 Charlson, 2008, The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients, J Clin Epidemiol, 61, 1234, 10.1016/j.jclinepi.2008.01.006 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther., 30, 239, 10.1038/clpt.1981.154 Informe Biobadaser fase III. 2016 [consultado Dic 2016]. Disponible en: https://biobadaser.ser.es. Carmona, 2009, Update of Biobadaser, Reumatol Clin., 5, 66, 10.1016/j.reuma.2008.11.007 Codreanu, 2015, Safety of biologics in rheumatoid arthritis: Data from randomized controlled trials and registries, Biologics, 9, 1 Singh, 2011, Adverse effects of biologics: A network meta-analysis and Cochrane overview, Cochrane Database System Rev., 10.1002/14651858.CD008794.pub2 De la Vega, 2013, Tercer reporte de eventos adversos con tratamientos biológicos en Argentina. Informe de registro Biobadasar, Rev Arg Reumatol., 24, 08 Gomez-Reino, 2012, Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the Spanish registry Biobadaser 2.0, Ann Rheum Dis., 71, 382, 10.1136/annrheumdis-2011-200302 Carmona, 2006, Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry Biobadaser, Arthritis Res Ther., 8, R72, 10.1186/ar1941 Heiberg, 2008, The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study, Arthritis Rheum., 59, 234, 10.1002/art.23333 Mok, 2014, Factors associated with withdrawal of the anti-TNFalpha biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry, Int J Rheum Dis, 17, 1 Duclos, 2006, Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients, J Rheum, 33, 2433 Neovius, 2015, Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab, Ann Rheum Dis., 74, 354, 10.1136/annrheumdis-2013-204128 Flouri, 2014, Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival, Semin Arthritis Rheum., 43, 447, 10.1016/j.semarthrit.2013.07.011 Machado-Alba, 2014, Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis, Rev Panam Salud Publica, 36, 396 Vega Miranda, 2014, Infecciones en pacientes con artritis reumatoide: medicamentos moduladores de la respuesta biológica versus fármacos modificadores de la enfermedad. Seguimiento a un año, Rev Colomb Reumatol., 21, 27 Sakai, 2015, Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: Results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry, Arthritis Res Ther., 17, 74, 10.1186/s13075-015-0583-8 Van Dartel, 2013, Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry, Ann Rheum Dis., 72, 895, 10.1136/annrheumdis-2012-201338 Macfarlane, 2015, The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment, BMC Musculoskelet Disord., 16, 347, 10.1186/s12891-015-0805-x